---
title: Therapeutic Targeting of Endothelial Ligands for L-selectin (PNAd) in a Sheep Model of Asthma
description: The homing of lymphocytes to peripheral lymph nodes is initiated by an adhesive interaction between L-selectin on lymphocytes and PNAd, a set of sialomucins that are constitutively displayed on high endothelial venules of lymph nodes.
---

[Science ](https://www.antibody.com/science)

# [Therapeutic Targeting of Endothelial Ligands for L-selectin (PNAd) in a Sheep Model of Asthma](https://www.antibody.com/science/therapeutic-targeting-of-endothelial-ligands-for-l-selectin-pnad-in-a-sheep-model-of-asthma)

 Written by [Antibody Solutions Research Team](https://www.antibody.com/science/author/antibody-research-team) | 3/16/05 7:12 PM

The homing of lymphocytes to peripheral lymph nodes is initiated by an adhesive interaction between L-selectin on lymphocytes and PNAd, a set of sialomucins that are constitutively displayed on high endothelial venules of lymph nodes. PNAd is defined by monoclonal antibody MECA-79 that recognizes a sulfated oligosaccharide carried by the sialomucins. This epitope overlaps with 6-sulfo sialyl Lewis x, a recognition determinant for L-selectin. Previous work has shown that administration of a L-selectin monoclonal antibody blocks both late-phase airway responses and airway hyperresponsiveness in a sheep model of asthma. We show here that airway-associated lymphoid collections from lungs of allergic sheep exhibited PNAd(+) venules as detected by immunostaining with MECA-79. The same vessels also expressed a GlcNAc-6-O-sulfotransferase known as HEC-GlcNAc6ST, which is known to contribute to the formation of the MECA-79 epitope in high endothelial venules of mouse lymph nodes. Intravenous administration of MECA-79 to allergic sheep significantly blunted both the late-phase airway response and airway hyperresponsiveness induced by airway allergen challenge. Furthermore, MECA-79 inhibited the accumulation of all classes of leukocytes in bronchoalveolar lavage fluid. These findings represent the first demonstration that targeting of PNAd has therapeutic efficacy in an inflammatory disease.

### Authors

Steven D Rosen, Durwin Tsay, Mark S Singer, Stefan Hemmerich, William M Abraham

[View full post](https://www.antibody.com/science/therapeutic-targeting-of-endothelial-ligands-for-l-selectin-pnad-in-a-sheep-model-of-asthma)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Antibody Solutions Research Team"
  },
  "dateModified" : "2024-12-12T14:55:44.253Z",
  "datePublished" : "2005-03-16T19:12:00Z",
  "headline" : "Therapeutic Targeting of Endothelial Ligands for L-selectin (PNAd) in a Sheep Model of Asthma",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1392,
    "url" : "https://www.antibody.com/hubfs/Research%20Blog%20Banner%20Images/V2/Antibody_Solutions_Research_banner-05.jpg",
    "width" : 3834
  },
  "mainEntityOfPage" : "https://www.antibody.com/science/therapeutic-targeting-of-endothelial-ligands-for-l-selectin-pnad-in-a-sheep-model-of-asthma",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Science"
  }
}
```